{"id":836918,"date":"2025-04-14T08:32:02","date_gmt":"2025-04-14T12:32:02","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/certara-launches-non-animal-navigator-solution-to-help-drug-developers-reduce-reliance-on-animal-testing\/"},"modified":"2025-04-14T08:32:02","modified_gmt":"2025-04-14T12:32:02","slug":"certara-launches-non-animal-navigator-solution-to-help-drug-developers-reduce-reliance-on-animal-testing","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/certara-launches-non-animal-navigator-solution-to-help-drug-developers-reduce-reliance-on-animal-testing\/","title":{"rendered":"Certara Launches Non-Animal Navigator\u2122 Solution to Help Drug Developers Reduce Reliance on Animal Testing"},"content":{"rendered":"

\nNew offering provides strategic guidance and AI-enabled biosimulation to navigate FDA\u2019s Roadmap to Reducing Animal Testing in Preclinical Safety Studies
\n<\/h2>\n
\n

RADNOR, Pa., April 14, 2025 (GLOBE NEWSWIRE) — Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced the launch of its Non-Animal Navigator<\/a>\u2122 solution designed to help biopharmaceutical companies lead the transition ignited by the FDA\u2019s Roadmap to Reducing Animal Testing in Preclinical Safety Studies.<\/em><\/a> The Roadmap marks a pivotal moment in drug development. Companies that act now can future-proof their portfolios, gaining competitive advantage through faster timelines, lower costs, and stronger predictive evidence.<\/p>\n

Globally, there are thousands of monoclonal antibodies and antibody-drug conjugates (ADCs) currently in the preclinical phase of development1<\/sup> across a broad range of therapeutic areas. Monoclonal antibodies are a key area in efforts to reduce animal testing, as biosimulation models often predict human outcomes as well as or better than, traditional animal studies. For over two decades, Certara has partnered with biopharmaceutical sponsors and regulatory agencies to integrate predictive, mechanistic models into the development and regulatory evaluation of biologics, including monoclonal antibodies.<\/p>\n

\u201cThe FDA announcement and roadmap pave the way for more model-informed drug development approaches that are predictive, efficient, and ethical,\u201d said William F. Feehery, Chief Executive Officer. \u201cIt is part of a growing industry adoption trend to use scientifically robust new approach methodologies (NAMs) like AI-enabled biosimulation to improve strategic decision-making and success rates at every phase of drug development.\u201d<\/p>\n

\u201cNavigating this paradigm shift requires deep regulatory insight, cross-functional expertise and modeling and simulation technology,\u201d said Patrick Smith, Senior Vice President of Translational Medicine. \u201cClients have begun reaching out about how to best lead their organizations through this major regulatory and scientific inflection point.\u201d<\/p>\n

Based on Certara\u2019s extensive experience working with\u00a0FDA, EMA, and other major health authorities, the Non-Animal Navigator is a flexible solution that ensures each client\u2019s development program is compliant, agile, and future ready. It offers clients:<\/p>\n